Cardiotoxicity in cancer patients treated with immune-checkpoint inhibitors

Immunotherapy (IO) represents one of the most promising therapeutic approaches in systemic cancer treatment. However, its broad clinical application revealed several important cardiovascular side effects which can limit treatment options, decrease patients' prognosis and quality of life. The aim of this study was to assess the prevalence of cardiovascular risk factors (CVRF) and the incidence of cardiovascular events (CVE) in patients treated with IO. This has been little researched, and the information we have is scarce.